Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
|Articles|August 1, 2017
Prequalified Cold-Chain Shipping Systems Are Designed for Various Durations
Cryopak’s CryoCube reusable temperature-controlled shipping systems are available in several insulation categories, and a tailored solution can be modeled using thermal modeling software.
Cryopak’s CryoCube line of reusable temperature-controlled shipping systems for cold chain packaging provides four insulation categories to satisfy a wider range of customer needs. In addition to the existing fabricated expanded polystyrene (EPS) and vacuum insulated panel (VIP) solutions, Cryopak now offers the CryoCube in molded EPS as well as polyurethane (PUR) varieties.
These containers offer flexibility and cost-efficiency in sustainable, prequalified cold-chain shipping solutions. Choices include an economical option with fabricated EPS for shorter durations (starting at 36 hours), a highest thermal performance option with VIP for extended durations (up to 120 hours), and anywhere in between with the new molded EPS and PUR models. The systems have been ergonomically designed to be lightweight and easy to packout.
Cryopak can now employ its new Ansys Fluent simulation software to help create a more tailored solution. This thermal modeling capability will allow the company to expedite an optimized, cost-efficient Cube design to meet specific customer requirements.
Source:
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.